clobazam has been researched along with Status Epilepticus in 19 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
Status Epilepticus: A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors administered clobazam (CLB) to treat status epilepticus in 16 patients from 3 to 62 years old." | 7.67 | [Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam]. ( Aguglia, U; Gastaut, H; Lugaresi, E; Tinuper, P, 1984) |
| "Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)." | 7.67 | Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986) |
| "Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties." | 5.43 | Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016) |
| "Clobazam was introduced after a median duration of 4 days and after a median of three failed antiepileptic drugs." | 5.42 | Clobazam: An effective add-on therapy in refractory status epilepticus. ( Ibrahim, M; Mohamed, W; Norris, G; Parker, D; Shah, A; Sivakumar, S, 2015) |
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 5.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| " However, extensive animal studies followed by clinical trials are necessary to develop a product suitable for emergencies of acute seizures in status epilepticus and patients suffering from drug tolerance and hepatic impairment on long-term use in treatment of epilepsy, schizophrenia, and anxiety." | 5.37 | Intranasal clobazam delivery in the treatment of status epilepticus. ( Ambikanandan, M; Ankur, K; Florence, K; Kumar, BA; Kumar, MA; Manisha, L, 2011) |
| " Clonazepam, chlorazepate, nitrazepam and clobazam are also prescribed as chronic treatment of various forms of epilepsy." | 4.76 | [Benzodiazepines in the treatment of epilepsy]. ( Loiseau, P, 1983) |
| "The authors administered clobazam (CLB) to treat status epilepticus in 16 patients from 3 to 62 years old." | 3.67 | [Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam]. ( Aguglia, U; Gastaut, H; Lugaresi, E; Tinuper, P, 1984) |
| "Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)." | 3.67 | Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986) |
| "Recent studies support the initial treatment of status epilepticus with early and aggressive benzodiazepine dosing." | 2.55 | Advancements in the critical care management of status epilepticus. ( Bauerschmidt, A; Claassen, J; Martin, A, 2017) |
| "Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties." | 1.43 | Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016) |
| "Clobazam was introduced after a median duration of 4 days and after a median of three failed antiepileptic drugs." | 1.42 | Clobazam: An effective add-on therapy in refractory status epilepticus. ( Ibrahim, M; Mohamed, W; Norris, G; Parker, D; Shah, A; Sivakumar, S, 2015) |
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 1.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| " However, extensive animal studies followed by clinical trials are necessary to develop a product suitable for emergencies of acute seizures in status epilepticus and patients suffering from drug tolerance and hepatic impairment on long-term use in treatment of epilepsy, schizophrenia, and anxiety." | 1.37 | Intranasal clobazam delivery in the treatment of status epilepticus. ( Ambikanandan, M; Ankur, K; Florence, K; Kumar, BA; Kumar, MA; Manisha, L, 2011) |
| "Spasms in series and hypsarrhythmia disappeared after treatment with high-dose phenobarbital; however, single spasms persisted with right-sided predominance, and polyspike activity in the left parieto-temporal areas preceded or coincided with these spasms." | 1.36 | Non-convulsive status epilepticus and audiogenic seizures complicating a patient with asymmetrical epileptic spasms. ( Hoshino, K; Komaki, H; Nakagawa, E; Saito, Y; Sakuma, H; Sasaki, M; Sugai, K, 2010) |
| "Three patients aged 16, 19, and 65 years with a 13- to 36-year history of partial epilepsy were receiving a therapeutic dosage of carbamazepine or phenobarbital plus either clobazam (CLB) or valproate (VPA)." | 1.30 | Negative myoclonic status due to antiepileptic drug tapering: report of three cases. ( Aguglia, U; Gambardella, A; Oliveri, RL; Quattrone, A; Russo, C; Zappia, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Sager, SG | 1 |
| Turkyilmaz, A | 1 |
| Gunbey, HP | 1 |
| Karatoprak, EY | 1 |
| Aslan, ES | 1 |
| Akın, Y | 1 |
| Specchio, N | 1 |
| Pietrafusa, N | 1 |
| Ferretti, A | 1 |
| Trivisano, M | 1 |
| Vigevano, F | 1 |
| Deng, L | 1 |
| Ma, A | 1 |
| Wood, N | 1 |
| Ardern-Holmes, S | 1 |
| van den Munckhof, B | 1 |
| Arzimanoglou, A | 1 |
| Perucca, E | 1 |
| van Teeseling, HC | 1 |
| Leijten, FSS | 1 |
| Braun, KPJ | 1 |
| Jansen, FE | 1 |
| Tolbert, D | 1 |
| Harris, SI | 1 |
| Bekersky, I | 1 |
| Lee, D | 1 |
| Isojarvi, J | 1 |
| Sivakumar, S | 1 |
| Ibrahim, M | 1 |
| Parker, D | 1 |
| Norris, G | 1 |
| Shah, A | 1 |
| Mohamed, W | 1 |
| Madžar, D | 1 |
| Geyer, A | 1 |
| Knappe, RU | 1 |
| Gollwitzer, S | 1 |
| Kuramatsu, JB | 1 |
| Gerner, ST | 1 |
| Hamer, HM | 1 |
| Huttner, HB | 1 |
| Bauerschmidt, A | 1 |
| Martin, A | 1 |
| Claassen, J | 1 |
| Carota, A | 1 |
| Novy, J | 1 |
| Rossetti, AO | 1 |
| Saito, Y | 1 |
| Sugai, K | 1 |
| Nakagawa, E | 1 |
| Sakuma, H | 1 |
| Komaki, H | 1 |
| Sasaki, M | 1 |
| Hoshino, K | 1 |
| Florence, K | 1 |
| Manisha, L | 1 |
| Kumar, BA | 1 |
| Ankur, K | 1 |
| Kumar, MA | 1 |
| Ambikanandan, M | 1 |
| Galimi, R | 1 |
| Yoshimura, K | 1 |
| Goldsmith, J | 1 |
| McKnight, C | 1 |
| Dickson, S | 1 |
| Heenan, M | 1 |
| Berezowski, R | 1 |
| Cooper, J | 1 |
| Feely, M | 1 |
| Loiseau, P | 1 |
| Gastaut, H | 2 |
| Tinuper, P | 2 |
| Aguglia, U | 3 |
| Lugaresi, E | 1 |
| Gambardella, A | 1 |
| Oliveri, RL | 1 |
| Russo, C | 1 |
| Zappia, M | 1 |
| Quattrone, A | 1 |
3 reviews available for clobazam and Status Epilepticus
| Article | Year |
|---|---|
Advancements in the critical care management of status epilepticus.
Topics: Acetamides; Administration, Intravenous; Anticonvulsants; Benzodiazepines; Clobazam; Critical Care; | 2017 |
Nonconvulsive status epilepticus in pediatric populations: diagnosis and management.
Topics: Acetazolamide; Anticonvulsants; Benzodiazepines; Child; Clobazam; Electroencephalography; Humans; Lo | 2012 |
[Benzodiazepines in the treatment of epilepsy].
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobazam | 1983 |
1 trial available for clobazam and Status Epilepticus
| Article | Year |
|---|---|
Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*).
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Clobazam; Electroencephalography; Epilepsy; Europe | 2020 |
15 other studies available for clobazam and Status Epilepticus
| Article | Year |
|---|---|
A novel de novo TET3 loss-of-function variant in a Turkish boy presenting with neurodevelopmental delay and electrical status epilepticus during slow-wave sleep.
Topics: Child; Clobazam; Dioxygenases; Electroencephalography; Humans; Infant; Male; Sleep; Sleep, Slow-Wave | 2023 |
Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome.
Topics: Anticonvulsants; Child; Clobazam; Drug Therapy, Combination; Epilepsies, Myoclonic; Fenfluramine; Hu | 2020 |
Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine.
Topics: Anticonvulsants; Clobazam; Enterovirus A, Human; Enterovirus Infections; Epilepsy; Fatal Outcome; Fe | 2020 |
Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
Topics: Adult; Aged; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Clobazam; Drug-Related Side Effect | 2014 |
Clobazam: An effective add-on therapy in refractory status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Benzodiazepines; Brain; Clobazam; Electroencephalography; | 2015 |
Effects of clobazam for treatment of refractory status epilepticus.
Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Female; Humans; Male; Mid | 2016 |
Symptomatic complex partial status epilepticus manifesting as utilization behavior of a mobile phone.
Topics: Anticonvulsants; Benzodiazepines; Brain Neoplasms; Cell Phone; Clobazam; Electroencephalography; Epi | 2009 |
Non-convulsive status epilepticus and audiogenic seizures complicating a patient with asymmetrical epileptic spasms.
Topics: Anticonvulsants; Benzodiazepines; Brain; Clobazam; Electroencephalography; Epilepsy, Reflex; Female; | 2010 |
Intranasal clobazam delivery in the treatment of status epilepticus.
Topics: Administration, Intranasal; Animals; Anticonvulsants; Benzodiazepines; Brain; Clobazam; Drug Stabili | 2011 |
A case of nonconvulsive status epilepticus associated with focal cortical dysplasia.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Diseases; Cerebral Cortex; Child; Child | 2003 |
Miconazole and clobazam; a useful interaction in Dravet's syndrome?
Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Drug Interactions; Drug Therapy, Combination; Fem | 2004 |
The difficulty in diagnosing non-convulsive status epilepticus during routine medical practice.
Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Diagnosis, Differential; Emergencies; Humans; Mida | 2004 |
[Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1984 |
Negative myoclonic status due to antiepileptic drug tapering: report of three cases.
Topics: Adolescent; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebral | 1997 |
Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobaz | 1986 |